Results 61 to 70 of about 8,708 (251)
New Perspectives on Antimicrobial Agents: Ceftolozane-Tazobactam
Antimicrobial Agents and Chemotherapy, 2021 Ceftolozane-tazobactam (C/T) is a new fifth-generation cephalosporin/beta-lactamase inhibitor combination approved by the Food and Drug Administration and the European Medicines Agency for treatment of complicated intraabdominal infections, complicated urinary tract infections, and hospital-acquired pneumonia in adult patients. This review will briefly
Bryan D. Lizza +4 more
openaire +4 more sources
Pharmacokinetics-pharmacodynamics of tazobactam in combination with cefepime in an in vitro infection model [PDF]
, 2017 We previously demonstrated that for tazobactam administered in combination with ceftolozane, the pharmacokinetic-pharmacodynamic (PK-PD) index that best described tazobactam efficacy was the percentage of the dosing interval that tazobactam ...
Ambrose, Paul G. +8 more
core +1 more source
Clinical Case Reports, Volume 14, Issue 4, April 2026.ABSTRACT Early prenatal screening at 26 + 6 weeks detected Citrobacter koseri vaginal colonization in an asymptomatic high‐risk gravida. Culture‐guided IV ceftazidime (susceptible per CLSI testing) eradicated the pathogen without maternal/fetal compromise.
Mario Assenza +2 more
wiley +1 more source
The 2018 Garrod Lecture: Preparing for the Black Swans of Resistance [PDF]
, 2018 The need for governments to encourage antibiotic development is widely agreed, with ‘Market Entry Rewards’ being suggested. Unless these are to be spread widely – which is unlikely given the $1 billion sums proposed– we should be wary, for this approach ...
Livermore, David
core +1 more source
Health Science Reports, Volume 9, Issue 4, April 2026.ABSTRACT Background and Aims Pneumonia is an inflammatory condition of the lower respiratory tract, commonly caused by infection and associated with substantial morbidity and healthcare utilization. The burden of pneumonia on healthcare is exacerbated by limited data on pathogenic causes and associated antimicrobial resistance (AMR). Here, we conducted
Radmir Sarsenov +7 more
wiley +1 more source
Journal of Global Antimicrobial ResistanceOBJECTIVES To evaluate the in vitro susceptibility of ESBL-producing Enterobacterales isolates to ceftolozane/tazobactam (C/T), a combination of tazobactam (a ß-lactamase inhibitor) and a new antipseudomonal cephalosporin.
Wei-Ting Yu +6 more
semanticscholar +1 more source
Clinical Infection in Practice, 2019 Background: Infective endocarditis (IE) due to multi-drug (MDR) and extensively drug-resistant (XDR) Pseudomonas aeruginosa is rare. MDR P. aeruginosa infections are increasingly reported worldwide, and the choice of effective antimicrobials is limited ...
A. Prescott +8 more
doaj +1 more source
identifying allosteric networks to fight antibiotics resistance [PDF]
, 2018 The rise of multi-drug resistance in bacterial pathogens is one of the grand challenges facing medical science. A major concern is the speed of development of β-lactamase-mediated resistance in Gram-negative species, thus putting at risk the efficacy of ...
Afsharikho, Hamidreza +9 more
core +1 more source
Clinical and Translational Science, Volume 19, Issue 4, April 2026.ABSTRACT Fluoroquinolones (FQs) are among the most frequently prescribed antibiotic classes worldwide. Despite their therapeutic versatility in treating bacterial infections, regulatory authorities recognized risks of persistent and potentially irreversible adverse effects, particularly peripheral neuropathy (PN).
Nimra Shamim +5 more
wiley +1 more source
Critical Care, 2021 Background Ceftolozane/tazobactam is approved for treatment of hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP) at double the dose approved for other infection sites.
Jean-François Timsit +14 more
doaj +1 more source